Bilaketaren emaitzak - Toshiyuki Tamai

  • Erakusten 1 - 10 emaitzak -- 10
Findu emaitzak
  1. 1
    Dose Finding of Lenvatinib in Subjects With Advanced Hepatocellular Carcinoma Based on Population Pharmacokinetic and Exposure-Response Analyses

    Dose Finding of Lenvatinib in Subjects With Advanced Hepatocellular Carcinoma Based on Population Pharmacokinetic and Exposure-Response Analyses nork Toshiyuki Tamai, Seiichi Hayato, Seiichiro Hojo, Takuya Suzuki, Takuji Okusaka, Kenji Ikeda, Hiromitsu Kumada

    Argitaratua 2017
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  2. 2
    Safety and Pharmacokinetics of Lenvatinib in Patients with Advanced Hepatocellular Carcinoma

    Safety and Pharmacokinetics of Lenvatinib in Patients with Advanced Hepatocellular Carcinoma nork Masafumi Ikeda, Takuji Okusaka, Shuichi Mitsunaga, Hideki Ueno, Toshiyuki Tamai, Takuya Suzuki, Seiichi Hayato, Tadashi Kadowaki, Kiwamu Okita, Hiromitsu Kumada

    Argitaratua 2015
    Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  3. 3
    Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma

    Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma nork Kenji Ikeda, Masatoshi Kudo, Seiji Kawazoe, Yukio Osaki, Masafumi Ikeda, Takuji Okusaka, Toshiyuki Tamai, Takuya Suzuki, Takashi Hisai, Seiichi Hayato, Kiwamu Okita, Hiromitsu Kumada

    Argitaratua 2016
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  4. 4
    Long-term follow-up and exploratory analysis of lenvatinib in patients with metastatic or recurrent thymic carcinoma: Results from the multicenter, phase 2 REMORA trial

    Long-term follow-up and exploratory analysis of lenvatinib in patients with metastatic or recurrent thymic carcinoma: Results from the multicenter, phase 2 REMORA trial nork Seiji Niho, Jun Sato, Miyako Satouchi, Shoichi Itoh, Yusuke Okuma, Hidenori Mizugaki, Haruyasu Murakami, Yasuhito Fujisaka, Toshiyuki Kozuki, Kenichi Nakamura, Ryunosuke Machida, Yuichiro Ohe, Toshiyuki Tamai, Hiroki Ikezawa, Noboru Yamamoto

    Argitaratua 2024
    Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  5. 5
    Baseline Liver Function and Subsequent Outcomes in the Phase 3 REFLECT Study of Patients with Unresectable Hepatocellular Carcinoma

    Baseline Liver Function and Subsequent Outcomes in the Phase 3 REFLECT Study of Patients with Unresectable Hepatocellular Carcinoma nork Arndt Vogel, Catherine Frenette, Max W. Sung, Bruno Daniele, Ari David Baron, Stephen L. Chan, Jean Frédéric Blanc, Toshiyuki Tamai, Min Ren, Howard J. Lim, Daniel H. Palmer, Yuko Takami, Masatoshi Kudo

    Argitaratua 2021
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  6. 6
    Lenvatinib dose, efficacy, and safety in the treatment of multiple malignancies

    Lenvatinib dose, efficacy, and safety in the treatment of multiple malignancies nork Robert J. Motzer, Matthew H. Taylor, T.R. Jeffry Evans, Takuji Okusaka, Hilary Glen, Gregory M. Lubiniecki, Corina E. Dutcus, Alan D. Smith, Chinyere E. Okpara, Ziad Hussein, Seiichi Hayato, Toshiyuki Tamai, Vicky Makker

    Argitaratua 2022
    Testu osoa
    Revisão
    Gogokoenen artean sartu
    Gorde:
  7. 7
    REFLECT—a phase 3 trial comparing efficacy and safety of lenvatinib to sorafenib for the treatment of unresectable hepatocellular carcinoma: an analysis of Japanese subset

    REFLECT—a phase 3 trial comparing efficacy and safety of lenvatinib to sorafenib for the treatment of unresectable hepatocellular carcinoma: an analysis of Japanese subset nork Tatsuya Yamashita, Masatoshi Kudo, Kenji Ikeda, Namiki Izumi, Ryosuke Tateishi, Masafumi Ikeda, Hiroshi Aikata, Yasunori Kawaguchi, Yoshiyuki Wada, Kazushi Numata, Yoshitaka Inaba, Ryoko Kuromatsu, Masahiro Kobayashi, Takuji Okusaka, Toshiyuki Tamai, Chifumi Kitamura, Kenichi Saito, Katsuya Haruna, Kiwamu Okita, Hiromitsu Kumada

    Argitaratua 2019
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  8. 8
    Overall survival and objective response in advanced unresectable hepatocellular carcinoma: A subanalysis of the REFLECT study

    Overall survival and objective response in advanced unresectable hepatocellular carcinoma: A subanalysis of the REFLECT study nork Masatoshi Kudo, Richard S. Finn, Shukui Qin, Kwang‐Hyub Han, Kenji Ikeda, Ann‐Lii Cheng, Arndt Vogel, Francesco Tovoli, Kazuomi Ueshima, Hiroshi Aikata, Carlos López, Marc Pracht, Zhiqiang Meng, Bruno Daniele, Joong‐Won Park, D. Palmer, Toshiyuki Tamai, Kenichi Saito, Corina E. Dutcus, Riccardo Lencioni

    Argitaratua 2022
    Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  9. 9
    Pharmacodynamic Biomarkers Predictive of Survival Benefit with Lenvatinib in Unresectable Hepatocellular Carcinoma: From the Phase III REFLECT Study

    Pharmacodynamic Biomarkers Predictive of Survival Benefit with Lenvatinib in Unresectable Hepatocellular Carcinoma: From the Phase III REFLECT Study nork Richard S. Finn, Masatoshi Kudo, Ann‐Lii Cheng, Lucjan Wyrwicz, Roger K.C. Ngan, Jean‐Frédéric Blanc, Ari David Baron, Arndt Vogel, Masafumi Ikeda, Fabio Piscaglia, Kwang‐Hyub Han, Shukui Qin, Yukinori Minoshima, Michio Kanekiyo, Min Ren, Ryo Dairiki, Toshiyuki Tamai, Corina E. Dutcus, Hiroki Ikezawa, Yasuhiro Funahashi, T.R. Jeffry Evans

    Argitaratua 2021
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  10. 10
    Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial

    Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial nork Masatoshi Kudo, Richard S. Finn, Shukui Qin, Kwang‐Hyub Han, Kenji Ikeda, Fabio Piscaglia, Ari David Baron, Joong‐Won Park, Guohong Han, Jacek Jassem, Jean Frédéric Blanc, Arndt Vogel, Д. В. Комов, T.R. Jeffry Evans, Carlos López, Corina E. Dutcus, Matthew Guo, Kenichi Saito, Silvija Kraljevic, Toshiyuki Tamai, Min Ren, Ann‐Lii Cheng

    Argitaratua 2018
    Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:

Bilaketa egiteko lanabesak: